相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
80.0%
招募中
1
20.0%
暂无批准数据
• A Phase 2A-2B clinical trial, Benfoteam, is underway to evaluate benfotiamine, a thiamine precursor, for slowing Alzheimer's progression in patients with mild cognitive impairment or mild dementia. • The trial, involving 406 participants across 50 sites, aims to determine the optimal safe dose of benfotiamine and its impact on global function and cognition over 18 months. • Benfotiamine targets thiamine deficiency, hypothesized to alter glucose metabolism in brain cells, potentially addressing the root cause of Alzheimer's disease, unlike current treatments focused on amyloid plaques. • Previous pilot studies showed promising results, with benfotiamine increasing blood thiamine levels and reducing cognitive decline, warranting further investigation into its efficacy.
- A nationwide Phase 2A-2B clinical trial, named BenfoTeam, is underway to assess benfotiamine, a synthetic form of vitamin B1, for treating mild cognitive impairment and early Alzheimer's disease. - The trial, spanning 50 sites across the U.S., aims to determine if benfotiamine improves cognitive function in individuals aged 50-89 with mild Alzheimer's or mild cognitive impairment. - Benfotiamine increases blood thiamine levels significantly, potentially addressing thiamine deficiencies observed in the brains of Alzheimer's patients, and is administered orally, unlike some other treatments. - The BenfoTeam trial seeks to enroll 406 participants and will last 18 months, with the goal of providing a cost-effective and accessible treatment option for diverse patient populations.
